China Pharma Holdings Inc. Overview
China Pharma Holdings, Inc., a company operating within the health care sector, is based in Haikou, China. The company, along with its subsidiary, is dedicated to the development and manufacturing of pharmaceutical products aimed at treating high-incidence and high-mortality diseases and medical conditions. Their products are marketed to hospitals and private sellers within the People’s Republic of China. China Pharma Holdings is listed on the NYSE American stock exchange, and more information can be found on their website at www.chinapharmaholdings.com .
Financial Snapshot
As of July 22, 2025, China Pharma Holdings Inc. closed at a price of $1.82 per share. The company’s market capitalization stands at $6,030,000 USD. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $3.40 on January 6, 2025, and a 52-week low of $1.20 on April 8, 2025.
Industry and Operations
Operating in the pharmaceutical industry, China Pharma Holdings focuses on creating products for human use, targeting diseases and medical conditions with high incidence and mortality rates. The company’s strategic focus on these areas highlights its commitment to addressing critical health challenges within China.
Market Presence
China Pharma Holdings markets its pharmaceutical products primarily within China, catering to both hospitals and private sellers. This domestic focus allows the company to tailor its offerings to the specific needs and regulatory environment of the Chinese healthcare market.
Conclusion
China Pharma Holdings, Inc. continues to play a significant role in the pharmaceutical industry by focusing on high-impact health issues. Despite recent stock price fluctuations, the company maintains a strategic position in the health care sector, with a clear focus on addressing critical medical needs in China.